ANDA 201896, held by Mylan. Ethinyl Estradiol; Norgestimate.
As of Nov 16, 2026, ANDA 201896 (Norgestimate And Ethinyl Estradiol), held by Mylan, was first approved by FDA on Jan 27, 2016, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 27, 2016 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Norgestimate And Ethinyl Estradiol0.035MG;0.25MG · tablet;oral-28 | Ethinyl Estradiol; Norgestimate | Discontinued |
| Jan 7, 2026 | Supplement 7Labeling · Standard review | Approved | None posted |
| Apr 29, 2022 | Supplement 5Labeling · Standard review | Approved | None posted |
| Nov 9, 2018 | Supplement 2Labeling · Standard review | Approved | None posted |
| Nov 9, 2018 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jan 27, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters